Sunitinib News and Research

RSS
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
Combination treatment improves outcomes in advanced kidney cancer patients

Combination treatment improves outcomes in advanced kidney cancer patients

In-depth study of kidney tumors reveals novel markers of response to immunotherapy

In-depth study of kidney tumors reveals novel markers of response to immunotherapy